At a glance
ClinicalIndex Comparison RecordN/ACompleted· 95 enrolled
Drug / intervention
Brentuximab Vedotin (Genetical Recombination)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Special Drug Use Surveillance for Adcetris Intravenous Infusion 50 Milligrams "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Hodgkin Lymphoma (Only Pediatric Patients)"
In Brief
An observational study evaluating Brentuximab Vedotin (Genetical Recombination) for Peripheral T Cell Lymphoma and Pediatric Hodgkin Lymphoma. Completed, enrolled 95 participants across 1 site.
Detailed Summary
The purpose of this survey is to examine the safety of adult patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma (PTCL) (excluding anaplastic large cell lymphoma (ALCL)) and pediatric patients with relapsed or refractory CD30-positive PTCL or Hodgkin lymphoma (HL) in the actual use of on concomitant Brentuximab Vedotin in routine clinical practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedDec 2019
Enrollment StartFeb 2020
Primary CompletionDec 2023
TodayJul 2026
First PostedDec 30, 2019
Enrollment StartFeb 14, 2020
Primary CompletionDec 13, 2023
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 6.5 years ago
Interventions
Brentuximab Vedotin (Genetical Recombination)drug
Brentuximab Vedotin Intravenous Infusion